<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00078403</url>
  </required_header>
  <id_info>
    <org_study_id>A5178</org_study_id>
    <secondary_id>10008</secondary_id>
    <nct_id>NCT00078403</nct_id>
  </id_info>
  <brief_title>Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)</brief_title>
  <official_title>Suppressive Long-Term Antiviral Management of Hepatitis C Virus (HCV) and HIV-1 Coinfected Subjects (SLAM-C)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      Infection with both HIV and hepatitis C virus (HCV) may result in serious and sometimes fatal
      liver disease. The purpose of this study was to test the effectiveness of long-term pegylated
      interferon alfa-2a (PEG-IFN) and ribavirin treatment in slowing liver disease progression in
      people infected with both HIV and HCV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rapid progression of liver disease to liver failure has been observed in people coinfected
      with HIV and HCV. This observation appears to be directly related to an increase in the rate
      of fibrotic progression in the liver compared to people infected with HCV alone. PEG-IFN and
      ribavirin are used in standard treatment of HCV. This study tested the effectiveness of using
      PEG-IFN in reducing the rate of liver fibrosis progression in participants coinfected with
      HIV and HCV who could not lower their HCV viral load to undetectable or who could not
      maintain their HCV viral load at undetectable on PEG-IFN and ribavirin treatment.

      Participants entered Step 1 (initial run-in period) to receive 12 weeks of 180 mcg PEG-IFN
      subcutaneously once weekly plus 1 to 1.2 g/day ribavirin based on body weight. At week 12,
      HCV RNA testing was performed.

      Participants with early virologic response (EVR), defined as &gt;=2 log10 drop in HCV RNA from
      baseline or undetectable HCV RNA (&lt;600 IU/ml with quantitative assay used in Step 1) at Week
      12, who had tolerated Step 1 treatment, entered into Step 3 to continue receiving the Step 1
      treatment for a total of 72 weeks (Arm C). Participants who did not meet the criteria for
      entry into Step 3 were discontinued from the study. In Step 3, participants were followed for
      an additional 24 weeks after treatment discontinuation to determine sustained virologic
      response (SVR). Initially, Step 3 participants who had a detectable HCV viral load (&gt;=60
      IU/ml with the qualitative assay used in Step 3) at Week 36 were eligible to enroll in Step
      2. After early closure of Step 2, such participants remained in Step 3 until study
      completion.

      Participants with &lt;2 log10 drop in HCV RNA from baseline and detectable HCV RNA at Week 12
      (non-EVR) discontinued Step 1 treatment. Non-EVRs who met the Step 2 eligibility criteria,
      were enrolled in Step 2 and randomized to receive 180 mcg PEG-IFN subcutaneously weekly for
      72 weeks (Arm A) or observation for 72 weeks (Arm B). Participants who did not meet the
      criteria for entry into Step 2 were discontinued from the study. Step 2 of the study was
      closed prematurely in May 2007 due to lower than expected progression rates among the
      participants in the observation arm such that the primary objective could not be reached.
      There were no safety concerns.

      Liver biopsies were conducted at study screening, and at Step 2 entry and exit until the
      early closure of Step 2. Medical history assessment, physical exams, and blood collection
      were conducted every 4-12 weeks for participants in Steps 1, 2, and 3. Participants were
      followed for up to 18 weeks in Step 1, followed by a total of 72 in Step 2 or by up to a
      total of 84 weeks in Step 3.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-scaled Change in Metavir Liver Fibrosis Score (SCMFS)</measure>
    <time_frame>Baseline and at week 72 or premature discontinuation</time_frame>
    <description>SCMFS is the difference between the Metavir fibrosis scores of the study exit and study entry liver biopsies where the difference is scaled to one year. The SCMFS assesses the annualized change in the severity of liver fibrosis on a continuous scale from -4.0 Metavir units per year (reduced fibrosis over time, a positive study outcome) to +4.0 Metavir units per year (increased fibrosis over time).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Detectable HCV Viral Load (&gt;= 60 IU/mL)</measure>
    <time_frame>Arms A and B: Weeks 0, 12, 24, 48 and 72; Arm C: Weeks 0, 12, 24, 36, 60, 72, 84</time_frame>
    <description>Qualitative plasma HCV viral load was categorized as less than 60 IU/mL vs greater than or equal to 60 IU/mL where 60 IU/mL is the lower limit of qualitative assay used in Steps 2 and 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-scaled Change in Ishak Liver Inflammation Score (SCIIS)</measure>
    <time_frame>Baseline and at week 72 or premature discontinuation</time_frame>
    <description>Liver biopsies were performed within 42 days prior to randomization between Arms A and B while the participant remained on PEG-IFN plus RBV (=entry biopsy) and again at week 72 or premature study discontinuation (=exit biopsy). SCIIS was defined as the difference between the Ishak inflammation score of the exit biopsy and the Ishak inflammation score of the entry biopsy, where the difference is scaled to one year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anemia</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>Number of participants with anemia by grade (defined by hemoglobin level in grams per deciliter; g/dL). DAIDS Toxicity Grading Table (1992) was used for grading where Grade 1 = hemoglobin of 8 to 9.4 g/dl; Grade 2 = 7 to 7.9 g/dl; Grade 3 = 6.5 to 6.9 g/dl; Grade 4 = below 6.5 g/dl.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Neutropenia</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>Number of participants with neutropenia by grade (defined by absolute neutrophil count [ANC] per cubic millimeter; mm^3). DAIDS Toxicity Grading Table (1992) was used for grading where Grade 1 = ANC of 1000 to 1500 /mm^3; Grade 2 = 750 to 999 /mm^3; Grade 3 = 500 to 749 /mm^3; Grade 4 = below 500 /mm^3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Thrombocytopenia</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>Number of participants with thrombocytopenia by grade (defined by platelet count per cubic millimeter; mm^3). DAIDS Toxicity Grading Table (1992) was used for grading where Grade 1 = platelets of 75,000 to 99,000 /mm^3; Grade 2 = 50,000 to 74,999 /mm^3; Grade 3 = 20,000 to 49,999 /mm^3; Grade 4 = below 20,000 /mm^3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Depression and/or Other Psychological Events</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>Depression and other psychological events. DAIDS Toxicity Grading Table (1992) was used for grading. The protocol required reporting of depression and other psychological events of Grade 3 or higher or if led to a change in treatment, regardless of grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With High-grade Signs and Symptoms or Laboratory Values</measure>
    <time_frame>Up to 96 Weeks</time_frame>
    <description>Number of participants with high-grade (Grade 3 or higher) signs and symptoms or laboratory values. DAIDS Toxicity Grading Table (1992) was used for grading where Grade 1 = transient/mild discomfort, no limitation in activity, no medical intervention; Grade 2 = mild/moderate limitation in activity, some assistance, no/minimal medical intervention; Grade 3 = marked limitation in activity, some assistance, medical intervention required); Grade 4 = extreme limitation in activity, significant medical intervention, assistance, hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Dose Modifications, Temporary Stops, and Premature Treatment Discontinuations</measure>
    <time_frame>Up to 96 Weeks</time_frame>
    <description>3-level categorical of the worst of 1) premature treatment discontinuation, 2) temporary stop or 3) dose reduction. For Arm C, the worst for either PEG-IFN or RBV is summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Adherent to Study Medications</measure>
    <time_frame>Arm A: at weeks 12, 24, 48 and 72. Arm C: at entry and weeks 12, 24, 48, 60.</time_frame>
    <description>A categorical variable with levels adherent and non-adherent based on participants' self report. For Arm A, adherence was defined as not missing PEG within 2 weeks of visit. For Arm C, adherence was defined as not missing any PEG within 2 weeks of visit and not missing RBV within 4 days of visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV Polymorphisms</measure>
    <time_frame>Entry and week 72 (Arms A and B only).</time_frame>
    <description>Due to premature closure of Arms A and B with insufficient number of participants for analysis, this outcome measure was not pursued.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV-specific Immune Response in Intrahepatic Lymphocytes</measure>
    <time_frame>Entry and week 72 (Arms A and B only).</time_frame>
    <description>Due to premature closure of Arms A and B with insufficient number of participants for analysis, this outcome measure was not pursued.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Undetectable HIV Viral Load (&lt;50 Copies/mL)</measure>
    <time_frame>Arms A and B: Weeks 0, 24, 48 and 72; Arm C: Weeks 0, 12, 24, 36, 48, 60, 72, 84</time_frame>
    <description>A blood sample was drawn to determine the HIV-1 viral load. HIV-1 viral load was categorized as &lt;50 copies/mL (undetectable) or &gt;=50 copies/mL (detectable). 50 is the lower limit of detection of the assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)</measure>
    <time_frame>Arms A and B: at entry and weeks 24, 48 and 72; Arm C: at entry and at weeks 12, 24, 36, 48, 72, 84 and 96.</time_frame>
    <description>Insulin resistance was evaluated by HOMA-IR, calculated as [fasting glucose (mg/dL) x fasting insulin (uIU/mL)]/405. Study protocol required fasting for at least 8 hours (nothing by mouth except medications and water) prior to specimen collection for fasting insulin and fasting glucose testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Virologic Response</measure>
    <time_frame>24 weeks after end of treatment</time_frame>
    <description>Sustained Virologic Response (SVR) was defined as undetectable HCV viral load (&lt;60 IU/ml) 24 weeks after treatment discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Used Antianorexia Agents, Such as Megestrol and Dronabinol</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>Use of antianorexia agents, such as megestrol and dronabinol at any time after pre-assignment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Prescription as Needed of Erythropoietin (EPO), Granulocyte Colony-stimulating Factor (GCSF), and Granulocyte-monocyte Colony-stimulating Factor (GM-CSF)</measure>
    <time_frame>At any time after pre-assignment</time_frame>
    <description>Prescription as needed of hematologic adjuvant therapies: erythropoietin (EPO), granulocyte colony-stimulating factor (GCSF), and granulocyte-monocyte colony-stimulating factor (GM-CSF) any time after pre-assignment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>Arms A and B: at entry and weeks 4, 8, 12, 16, 24, 32, 40, 48, 56, 64 and 72; Arm C: at entry and weeks 4, 8, 12, 16, 24, 36, 48, 72, 84 and 96.</time_frame>
    <description>Participant weight in kilograms.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">333</enrollment>
  <condition>HIV Infections</condition>
  <condition>Hepatitis C</condition>
  <condition>Liver Disease</condition>
  <arm_group>
    <arm_group_label>Arm A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: OL (PEG-IFN, RBV) then OL Randomized (Observation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: OL (PEG-IFN, RBV) then OL (PEG-IFN, RBV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At week 12 (end of initial run-in period, Step 1) participants were found to have undetectable HCV RNA (HCV RNA &lt;600 IU/mL) or at least a 2 log10 decrease in HCV RNA from baseline. Participants entered Step 3 and were assigned to continue the run-in treatment (PEG-IFN 180 mcg weekly &amp; RBV1-1.2 g/day based on weight) for a total of 72 weeks. At week 36, participants who had detectable HCV RNA (HCV RNA &gt;=60 IU/mL using a qualitative assay) could enter Step 2 and be randomized to OL PEG-IFN or Observation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>180 mcg PEG-IFN subcutaneously</description>
    <arm_group_label>Arm A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)</arm_group_label>
    <arm_group_label>Arm B: OL (PEG-IFN, RBV) then OL Randomized (Observation)</arm_group_label>
    <arm_group_label>Arm C: OL (PEG-IFN, RBV) then OL (PEG-IFN, RBV)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>One tablet or capsule containing ribavirin 200 mg</description>
    <arm_group_label>Arm A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)</arm_group_label>
    <arm_group_label>Arm B: OL (PEG-IFN, RBV) then OL Randomized (Observation)</arm_group_label>
    <arm_group_label>Arm C: OL (PEG-IFN, RBV) then OL (PEG-IFN, RBV)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Step 1:

          -  HIV infected

          -  Stable antiretroviral therapy for at least 8 weeks prior to study entry OR have not
             received any antiretroviral therapy for at least 4 weeks prior to entry

          -  HIV viral load less than 50,000 copies/ml within 6 weeks prior to study entry

          -  CD4 count greater than 200 cells/mm^3 within 6 weeks prior to study entry

          -  Hepatitis C virus (HCV) infected

          -  Either HCV treatment naive OR previously treated with interferon (IFN), PEG-IFN, IFN
             and ribavirin, or PEG-IFN and ribavirin for at least 12 weeks and HCV RNA positive
             following their last course of HCV treatment

          -  Chronic liver disease consistent with chronic viral hepatitis

          -  At least stage I fibrosis on a liver biopsy obtained within 104 weeks of study entry

          -  If at stage VI fibrosis, Child-Pugh-Turcotte (CPT) score of 5 or less and no more than
             Child-Pugh Class A

          -  Liver enzyme (alanine aminotransferase [ALT], aspartate aminotransferase [AST], and
             alkaline phosphatase) levels 10 times or less than upper limit of normal

          -  Agree to use acceptable methods of contraception

        Inclusion Criteria for Step 2:

          -  Currently enrolled in Step 1 or received 12 weeks of PEG-IFN plus ribavirin outside
             this study

          -  Detectable HCV viral load and &lt;2 log10 decrease from baseline in plasma/serum HCV
             viral load at Week 12.

          -  On Step 1 study treatment for no longer than 18 weeks

        Inclusion Criteria for Step 3:

          -  Currently enrolled in Step 1

          -  Undetectable HCV RNA or a 2-log or greater decrease in plasma/serum HCV viral load.

          -  On Step 1 study treatment for no longer than 18 weeks

        Exclusion Criteria for Steps 1 and 3:

          -  Have received HCV treatment within 4 weeks of study entry. Participants currently
             receiving treatment for HCV, if non-EVRs, were considered for direct entry into Step
             2, without the run-in period in Step 1.

          -  Could not tolerate treatment with PEG-IFN, defined as missing 3 or more consecutive
             PEG-IFN doses during the first 12 weeks or a total of 5 doses prior to Step 3 entry.
             Participants who have missed doses of ribavirin will not be excluded from Step 3
             entry.

          -  Use of granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage
             colony-stimulating factor (GM-CSF) within 14 days prior to study entry

          -  Alpha feto protein level 400 ng/ml or greater within 24 weeks prior to study entry, or
             alpha feto protein level greater than 50 ng/ml and less than 400 ng/ml (unless
             computed tomography [CT] scan or magnetic resonance imaging [MRI] shows no evidence of
             hepatic tumor) within 24 weeks prior to study entry

          -  Decompensated liver disease, including presence or history of ascites, variceal
             bleeding, and brain or nervous system damage as a result of liver damage

          -  Other causes of significant liver disease, including hepatitis A or B, excess iron
             deposits in the liver (hemochromatosis), or homozygote alpha-1 antitrypsin deficiency

          -  Use of systemic corticosteroids, interferon gamma, TNF-alpha inhibitors, rifampin,
             rifabutin, pyrazinamide, isoniazid, ganciclovir, or hydroxyurea within 2 weeks prior
             to study entry

          -  Known allergy/sensitivity to PEG-IFN alfa-2a or ribavirin or their formulations

          -  History of uncontrolled seizure disorders

          -  Clinically active thyroid disease. Thyroid hormone replacement therapy is permitted,
             but thyroid-stimulating hormone (TSH) and free thyroxine index (FTI) must be in normal
             range.

          -  History of autoimmune processes, including Crohn's disease, ulcerative colitis, severe
             psoriasis, and rheumatoid arthritis, that may be made worse by interferon use

          -  Any systemic antineoplastic or immunomodulatory treatment or radiation within 24 weeks
             prior to study entry

          -  Malignancy

          -  Active coronary artery disease within 24 weeks prior to study entry

          -  Acute or active AIDS-defining opportunistic infections within 12 weeks of study entry

          -  Hemoglobin abnormalities (e.g., thalassemia) or any other cause of or tendency to
             break down red blood cells (hemolysis)

          -  History of major organ transplantation with an existing functional graft

          -  Active drug or alcohol use or dependence that, in the opinion of the investigator,
             would interfere with study adherence

          -  Uncontrolled or active depression or other psychiatric disorder, such as untreated
             Grade 3 psychiatric disorder, medically untreatable Grade 3 disorder, or any
             hospitalization within 52 weeks of study entry that, in the opinion of the
             investigator, may interfere with study requirements

          -  Other serious illness or chronic medical condition that, in the opinion of the
             investigator, may have prevented participant's completion of the study

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth E. Sherman, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raymond Chung, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Harvard/Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Therapeutics CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35924-2050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033-1079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Center CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford AIDS Clinical Trials Unit CRS</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304-5350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Antiviral Research Center CRS</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsf Hiv/Aids Crs</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Clara Valley Med. Ctr.</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University CRS (GU CRS)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Hawaii at Manoa, Leahi Hosp.</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ. School of Medicine, Infectious Disease Research Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ. School of Medicine, Wishard Memorial</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital CRS (MGH CRS)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hosp. ACTG CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Med. Ctr., ACTG CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Therapeutics (WT) CRS</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110-1010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Nebraska Med. Ctr., Durham Outpatient Ctr.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-9500</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Med. Ctr., ACTU</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Chelsea CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Univ. HIV/AIDS CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Uptown CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia P&amp;S CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trillium Health ACTG CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McCree McCuller Wellness Ctr. at the Connection, Infectious Disease Unit</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Rochester ACTG CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chapel Hill CRS</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati CRS</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth CRS</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Pennsylvania Health System, Presbyterian Med. Ctr.</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh CRS</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital Clinical Research Site (TMH CRS) CRS</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Therapeutics (VT) CRS</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Texas Southwestern Med. Ctr., Amelia Court Continuity Clinic</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235-9173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Texas Medical Branch, ACTU</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puerto Rico AIDS Clinical Trials Unit CRS</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bräu N. Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin. Semin Liver Dis. 2005 Feb;25(1):33-51. Review.</citation>
    <PMID>15731996</PMID>
  </reference>
  <reference>
    <citation>Borgia G, Reynaud L, Gentile I, Piazza M. HIV and hepatitis C virus: facts and controversies. Infection. 2003 Aug;31(4):232-40. Review.</citation>
    <PMID>14562947</PMID>
  </reference>
  <reference>
    <citation>Khalili M, Bernstein D, Lentz E, Barylski C, Hoffman-Terry M. Pegylated interferon alpha-2a with or without ribavirin in HCV/HIV coinfection: partially blinded, randomized multicenter trial. Dig Dis Sci. 2005 Jun;50(6):1148-55.</citation>
    <PMID>15986873</PMID>
  </reference>
  <reference>
    <citation>Neau D, Trimoulet P, Winnock M, Rullier A, Le Bail B, Lacoste D, Ragnaud JM, Bioulac-Sage P, Lafon ME, Chêne G, Dupon M; ROCO Study Group. Comparison of 2 regimens that include interferon-alpha-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients. Clin Infect Dis. 2003 Jun 15;36(12):1564-71. Epub 2003 Jun 3.</citation>
    <PMID>12802757</PMID>
  </reference>
  <reference>
    <citation>Torriani FJ, Ribeiro RM, Gilbert TL, Schrenk UM, Clauson M, Pacheco DM, Perelson AS. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis. 2003 Nov 15;188(10):1498-507. Epub 2003 Nov 13.</citation>
    <PMID>14624375</PMID>
  </reference>
  <reference>
    <citation>Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT; APRICOT Study Group. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004 Jul 29;351(5):438-50.</citation>
    <PMID>15282351</PMID>
  </reference>
  <reference>
    <citation>The Division of AIDS Table for Grading the Severity of Adult Adverse Events (DAIDS AE Grading Table), August 1992.</citation>
  </reference>
  <reference>
    <citation>Manual for Expedited Reporting of Adverse Events to Division of AIDS (DAIDS EAE Manual), May 2004.</citation>
  </reference>
  <results_reference>
    <citation>Butt AA, Umbleja T, Andersen JW, Chung RT, Sherman KE; ACTG A5178 Study Team. The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin. Aliment Pharmacol Ther. 2011 Jun;33(11):1234-44. doi: 10.1111/j.1365-2036.2011.04648.x. Epub 2011 Mar 29.</citation>
    <PMID>21535051</PMID>
  </results_reference>
  <results_reference>
    <citation>Sherman KE, Andersen JW, Butt AA, Umbleja T, Alston B, Koziel MJ, Peters MG, Sulkowski M, Goodman ZD, Chung RT; AIDS Clinical Trials Group A5178 Study Team. Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C). J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):597-605. doi: 10.1097/QAI.0b013e3181f6d916.</citation>
    <PMID>20921898</PMID>
  </results_reference>
  <results_reference>
    <citation>Chung RT, Umbleja T, Chen JY, Andersen JW, Butt AA, Sherman KE; Actg A5178 Study Team. Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients. HIV Clin Trials. 2012 Mar-Apr;13(2):70-82. doi: 10.1310/hct1302-70.</citation>
    <PMID>22510354</PMID>
  </results_reference>
  <results_reference>
    <citation>Butt AA, Umbleja T, Andersen JW, Sherman KE, Chung RT; ACTG A5178 Study Team. Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in Hepatitis C virus/HIV-coinfected persons: the AIDS Clinical Trials Group A5178 Study. Clin Infect Dis. 2012 Sep;55(5):631-8. Epub 2012 May 4.</citation>
    <PMID>22563020</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2004</study_first_submitted>
  <study_first_submitted_qc>February 24, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2004</study_first_posted>
  <results_first_submitted>November 5, 2010</results_first_submitted>
  <results_first_submitted_qc>March 30, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 27, 2011</results_first_posted>
  <last_update_submitted>November 30, 2016</last_update_submitted>
  <last_update_submitted_qc>November 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>People with hepatitis C virus (HCV)/HIV coinfection were recruited for participation in this study.</recruitment_details>
      <pre_assignment_details>330 participants were to receive 12 weeks of PEG+RBV to determine EVR status. Of the 330, 33 discontinued prior to week 12; 113 were non-EVRs, 80 of whom were randomized between Arms A and B; and 184 achieved EVR, 170 of whom were eligible to continue. 169 of the 170 were assigned to Arm C and one was inadvertently randomized between Arms A and B.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)</title>
          <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.</description>
        </group>
        <group group_id="P2">
          <title>OL (PEG-IFN, RBV) Then OL Randomized (Observation)</title>
          <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).</description>
        </group>
        <group group_id="P3">
          <title>OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)</title>
          <description>At week 12 (end of initial run-in period, Step 1) participants were found to have undetectable HCV RNA (HCV RNA &lt;600 IU/mL) or at least a 2 log10 decrease in HCV RNA from baseline. Participants entered Step 3 and were assigned to continue the run-in treatment (PEG-IFN 180 mcg weekly &amp; RBV1-1.2 g/day based on weight) for a total of 72 weeks. At week 36, participants who had detectable HCV RNA (HCV RNA &gt;=60 IU/mL using a qualitative assay) could enter Step 2 and be randomized to OL PEG-IFN or Observation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44">Eligible at pre-assignment (40), direct (2), Arm C week 36 non-response (1), EVR inadvertently (1).</participants>
                <participants group_id="P2" count="42">Eligible at pre-assignment (40), direct (1), Arm C week 36 non-response (1).</participants>
                <participants group_id="P3" count="169"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="141"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All Arm A, B and C participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)</title>
          <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.</description>
        </group>
        <group group_id="B2">
          <title>OL (PEG-IFN, RBV) Then OL Randomized (Observation)</title>
          <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).</description>
        </group>
        <group group_id="B3">
          <title>OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)</title>
          <description>At week 12 (end of initial run-in period, Step 1) participants were found to have undetectable HCV RNA (HCV RNA &lt;600 IU/mL) or at least a 2 log10 decrease in HCV RNA from baseline. Participants entered Step 3 and were assigned to continue the run-in treatment (PEG-IFN 180 mcg weekly &amp; RBV1-1.2 g/day based on weight) for a total of 72 weeks. At week 36, participants who had detectable HCV RNA (HCV RNA &gt;=60 IU/mL using a qualitative assay) could enter Step 2 and be randomized to OL PEG-IFN or Observation.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="169"/>
            <count group_id="B4" value="255"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="169"/>
                    <measurement group_id="B4" value="255"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.8" spread="6.7"/>
                    <measurement group_id="B2" value="48.1" spread="5.8"/>
                    <measurement group_id="B3" value="47.2" spread="7.1"/>
                    <measurement group_id="B4" value="47.6" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="150"/>
                    <measurement group_id="B4" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="168"/>
                    <measurement group_id="B4" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time-scaled Change in Metavir Liver Fibrosis Score (SCMFS)</title>
        <description>SCMFS is the difference between the Metavir fibrosis scores of the study exit and study entry liver biopsies where the difference is scaled to one year. The SCMFS assesses the annualized change in the severity of liver fibrosis on a continuous scale from -4.0 Metavir units per year (reduced fibrosis over time, a positive study outcome) to +4.0 Metavir units per year (increased fibrosis over time).</description>
        <time_frame>Baseline and at week 72 or premature discontinuation</time_frame>
        <population>62 Arm A and B participants who had follow-up liver biopsy performed or those who had Week 72 potential as of May 2, 2007 but no follow-up liver biopsy. In the unadjusted ITT analysis, the participants without SCMFS available were assigned the highest SCMFS (+2).</population>
        <group_list>
          <group group_id="O1">
            <title>A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).</description>
          </group>
          <group group_id="O3">
            <title>C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)</title>
            <description>At week 12 (end of initial run-in period, Step 1) participants were found to have undetectable HCV RNA (HCV RNA &lt;600 IU/mL) or at least a 2 log10 decrease in HCV RNA from baseline. Participants entered Step 3 and were assigned to continue the run-in treatment (PEG-IFN 180 mcg weekly &amp; RBV1-1.2 g/day based on weight) for a total of 72 weeks. At week 36, participants who had detectable HCV RNA (HCV RNA &gt;=60 IU/mL using a qualitative assay) could enter Step 2 and be randomized to OL PEG-IFN or Observation.</description>
          </group>
        </group_list>
        <measure>
          <title>Time-scaled Change in Metavir Liver Fibrosis Score (SCMFS)</title>
          <description>SCMFS is the difference between the Metavir fibrosis scores of the study exit and study entry liver biopsies where the difference is scaled to one year. The SCMFS assesses the annualized change in the severity of liver fibrosis on a continuous scale from -4.0 Metavir units per year (reduced fibrosis over time, a positive study outcome) to +4.0 Metavir units per year (increased fibrosis over time).</description>
          <population>62 Arm A and B participants who had follow-up liver biopsy performed or those who had Week 72 potential as of May 2, 2007 but no follow-up liver biopsy. In the unadjusted ITT analysis, the participants without SCMFS available were assigned the highest SCMFS (+2).</population>
          <units>Metavir units per one year (52 weeks)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1.37"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Accrual and follow-up on Arms A and B were halted for futility at the first independent interim review of the primary endpoint conducted on May 2, 2007.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.58</p_value>
            <p_value_desc>P-value is pre-specified 1-sided test that PEG slows liver fibrosis progression. Accrual and follow-up on Arms A and B were halted at interim review for lack of fibrosis progression in Arm B (control arm). P-value is unadjusted for interim analysis.</p_value_desc>
            <method>Exact Wilcoxon rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Detectable HCV Viral Load (&gt;= 60 IU/mL)</title>
        <description>Qualitative plasma HCV viral load was categorized as less than 60 IU/mL vs greater than or equal to 60 IU/mL where 60 IU/mL is the lower limit of qualitative assay used in Steps 2 and 3.</description>
        <time_frame>Arms A and B: Weeks 0, 12, 24, 48 and 72; Arm C: Weeks 0, 12, 24, 36, 60, 72, 84</time_frame>
        <population>All Arm A, B and C participants</population>
        <group_list>
          <group group_id="O1">
            <title>A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).</description>
          </group>
          <group group_id="O3">
            <title>C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)</title>
            <description>At week 12 (end of initial run-in period, Step 1) participants were found to have undetectable HCV RNA (HCV RNA &lt;600 IU/mL) or at least a 2 log10 decrease in HCV RNA from baseline. Participants entered Step 3 and were assigned to continue the run-in treatment (PEG-IFN 180 mcg weekly &amp; RBV1-1.2 g/day based on weight) for a total of 72 weeks. At week 36, participants who had detectable HCV RNA (HCV RNA &gt;=60 IU/mL using a qualitative assay) could enter Step 2 and be randomized to OL PEG-IFN or Observation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Detectable HCV Viral Load (&gt;= 60 IU/mL)</title>
          <description>Qualitative plasma HCV viral load was categorized as less than 60 IU/mL vs greater than or equal to 60 IU/mL where 60 IU/mL is the lower limit of qualitative assay used in Steps 2 and 3.</description>
          <population>All Arm A, B and C participants</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0--Number of participants with HCV RNA data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0--Number of participants with detectable HCV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12--Number of participants with HCV RNA data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12-Number of participants with detectable HCV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24--Number of participants with HCV RNA data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24-Number of participants with detectable HCV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36--Number of participants with HCV RNA data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36-Number of participants with detectable HCV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Test not specified in protocol at this time point.</measurement>
                    <measurement group_id="O2" value="NA">Test not specified in protocol at this time point.</measurement>
                    <measurement group_id="O3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48--Number of participants with HCV RNA data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48-Number of participants with detectable HCV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="NA">Test not specified in protocol at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60--Number of participants with HCV RNA data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60-Number of participants with detectable HCV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Test not specified in protocol at this time point.</measurement>
                    <measurement group_id="O2" value="NA">Test not specified in protocol at this time point.</measurement>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72--Number of participants with HCV RNA data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72-Number of participants with detectable HCV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84--Number of participants with HCV RNA data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84-Number of participants with detectable HCV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Test not specified in protocol at this time point.</measurement>
                    <measurement group_id="O2" value="NA">Test not specified in protocol at this time point.</measurement>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-scaled Change in Ishak Liver Inflammation Score (SCIIS)</title>
        <description>Liver biopsies were performed within 42 days prior to randomization between Arms A and B while the participant remained on PEG-IFN plus RBV (=entry biopsy) and again at week 72 or premature study discontinuation (=exit biopsy). SCIIS was defined as the difference between the Ishak inflammation score of the exit biopsy and the Ishak inflammation score of the entry biopsy, where the difference is scaled to one year.</description>
        <time_frame>Baseline and at week 72 or premature discontinuation</time_frame>
        <population>All participants with SCIIS available (Complete Cases)</population>
        <group_list>
          <group group_id="O1">
            <title>A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).</description>
          </group>
          <group group_id="O3">
            <title>C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)</title>
            <description>At week 12 (end of initial run-in period, Step 1) participants were found to have undetectable HCV RNA (HCV RNA &lt;600 IU/mL) or at least a 2 log10 decrease in HCV RNA from baseline. Participants entered Step 3 and were assigned to continue the run-in treatment (PEG-IFN 180 mcg weekly &amp; RBV1-1.2 g/day based on weight) for a total of 72 weeks. At week 36, participants who had detectable HCV RNA (HCV RNA &gt;=60 IU/mL using a qualitative assay) could enter Step 2 and be randomized to OL PEG-IFN or Observation.</description>
          </group>
        </group_list>
        <measure>
          <title>Time-scaled Change in Ishak Liver Inflammation Score (SCIIS)</title>
          <description>Liver biopsies were performed within 42 days prior to randomization between Arms A and B while the participant remained on PEG-IFN plus RBV (=entry biopsy) and again at week 72 or premature study discontinuation (=exit biopsy). SCIIS was defined as the difference between the Ishak inflammation score of the exit biopsy and the Ishak inflammation score of the entry biopsy, where the difference is scaled to one year.</description>
          <population>All participants with SCIIS available (Complete Cases)</population>
          <units>Ishak units per one year (52 weeks)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-0.75" upper_limit="1.79"/>
                    <measurement group_id="O2" value="1.31" lower_limit="0" upper_limit="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anemia</title>
        <description>Number of participants with anemia by grade (defined by hemoglobin level in grams per deciliter; g/dL). DAIDS Toxicity Grading Table (1992) was used for grading where Grade 1 = hemoglobin of 8 to 9.4 g/dl; Grade 2 = 7 to 7.9 g/dl; Grade 3 = 6.5 to 6.9 g/dl; Grade 4 = below 6.5 g/dl.</description>
        <time_frame>Up to 96 weeks</time_frame>
        <population>All Arm A, B and C participants</population>
        <group_list>
          <group group_id="O1">
            <title>A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).</description>
          </group>
          <group group_id="O3">
            <title>C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)</title>
            <description>At week 12 (end of initial run-in period, Step 1) participants were found to have undetectable HCV RNA (HCV RNA &lt;600 IU/mL) or at least a 2 log10 decrease in HCV RNA from baseline. Participants entered Step 3 and were assigned to continue the run-in treatment (PEG-IFN 180 mcg weekly &amp; RBV1-1.2 g/day based on weight) for a total of 72 weeks. At week 36, participants who had detectable HCV RNA (HCV RNA &gt;=60 IU/mL using a qualitative assay) could enter Step 2 and be randomized to OL PEG-IFN or Observation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anemia</title>
          <description>Number of participants with anemia by grade (defined by hemoglobin level in grams per deciliter; g/dL). DAIDS Toxicity Grading Table (1992) was used for grading where Grade 1 = hemoglobin of 8 to 9.4 g/dl; Grade 2 = 7 to 7.9 g/dl; Grade 3 = 6.5 to 6.9 g/dl; Grade 4 = below 6.5 g/dl.</description>
          <population>All Arm A, B and C participants</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anemia &gt;= Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Neutropenia</title>
        <description>Number of participants with neutropenia by grade (defined by absolute neutrophil count [ANC] per cubic millimeter; mm^3). DAIDS Toxicity Grading Table (1992) was used for grading where Grade 1 = ANC of 1000 to 1500 /mm^3; Grade 2 = 750 to 999 /mm^3; Grade 3 = 500 to 749 /mm^3; Grade 4 = below 500 /mm^3.</description>
        <time_frame>Up to 96 weeks</time_frame>
        <population>All Arm A, B and C participants</population>
        <group_list>
          <group group_id="O1">
            <title>A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).</description>
          </group>
          <group group_id="O3">
            <title>C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)</title>
            <description>At week 12 (end of initial run-in period, Step 1) participants were found to have undetectable HCV RNA (HCV RNA &lt;600 IU/mL) or at least a 2 log10 decrease in HCV RNA from baseline. Participants entered Step 3 and were assigned to continue the run-in treatment (PEG-IFN 180 mcg weekly &amp; RBV1-1.2 g/day based on weight) for a total of 72 weeks. At week 36, participants who had detectable HCV RNA (HCV RNA &gt;=60 IU/mL using a qualitative assay) could enter Step 2 and be randomized to OL PEG-IFN or Observation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Neutropenia</title>
          <description>Number of participants with neutropenia by grade (defined by absolute neutrophil count [ANC] per cubic millimeter; mm^3). DAIDS Toxicity Grading Table (1992) was used for grading where Grade 1 = ANC of 1000 to 1500 /mm^3; Grade 2 = 750 to 999 /mm^3; Grade 3 = 500 to 749 /mm^3; Grade 4 = below 500 /mm^3.</description>
          <population>All Arm A, B and C participants</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neutropenia &gt;= Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Thrombocytopenia</title>
        <description>Number of participants with thrombocytopenia by grade (defined by platelet count per cubic millimeter; mm^3). DAIDS Toxicity Grading Table (1992) was used for grading where Grade 1 = platelets of 75,000 to 99,000 /mm^3; Grade 2 = 50,000 to 74,999 /mm^3; Grade 3 = 20,000 to 49,999 /mm^3; Grade 4 = below 20,000 /mm^3.</description>
        <time_frame>Up to 96 weeks</time_frame>
        <population>All Arm A, B and C participants</population>
        <group_list>
          <group group_id="O1">
            <title>A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).</description>
          </group>
          <group group_id="O3">
            <title>C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)</title>
            <description>At week 12 (end of initial run-in period, Step 1) participants were found to have undetectable HCV RNA (HCV RNA &lt;600 IU/mL) or at least a 2 log10 decrease in HCV RNA from baseline. Participants entered Step 3 and were assigned to continue the run-in treatment (PEG-IFN 180 mcg weekly &amp; RBV1-1.2 g/day based on weight) for a total of 72 weeks. At week 36, participants who had detectable HCV RNA (HCV RNA &gt;=60 IU/mL using a qualitative assay) could enter Step 2 and be randomized to OL PEG-IFN or Observation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Thrombocytopenia</title>
          <description>Number of participants with thrombocytopenia by grade (defined by platelet count per cubic millimeter; mm^3). DAIDS Toxicity Grading Table (1992) was used for grading where Grade 1 = platelets of 75,000 to 99,000 /mm^3; Grade 2 = 50,000 to 74,999 /mm^3; Grade 3 = 20,000 to 49,999 /mm^3; Grade 4 = below 20,000 /mm^3.</description>
          <population>All Arm A, B and C participants</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Thrombocytopenia &gt;= Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Depression and/or Other Psychological Events</title>
        <description>Depression and other psychological events. DAIDS Toxicity Grading Table (1992) was used for grading. The protocol required reporting of depression and other psychological events of Grade 3 or higher or if led to a change in treatment, regardless of grade.</description>
        <time_frame>Up to 96 weeks</time_frame>
        <population>All Arm A, B and C participants</population>
        <group_list>
          <group group_id="O1">
            <title>A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).</description>
          </group>
          <group group_id="O3">
            <title>C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)</title>
            <description>At week 12 (end of initial run-in period, Step 1) participants were found to have undetectable HCV RNA (HCV RNA &lt;600 IU/mL) or at least a 2 log10 decrease in HCV RNA from baseline. Participants entered Step 3 and were assigned to continue the run-in treatment (PEG-IFN 180 mcg weekly &amp; RBV1-1.2 g/day based on weight) for a total of 72 weeks. At week 36, participants who had detectable HCV RNA (HCV RNA &gt;=60 IU/mL using a qualitative assay) could enter Step 2 and be randomized to OL PEG-IFN or Observation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Depression and/or Other Psychological Events</title>
          <description>Depression and other psychological events. DAIDS Toxicity Grading Table (1992) was used for grading. The protocol required reporting of depression and other psychological events of Grade 3 or higher or if led to a change in treatment, regardless of grade.</description>
          <population>All Arm A, B and C participants</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any psychological</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With High-grade Signs and Symptoms or Laboratory Values</title>
        <description>Number of participants with high-grade (Grade 3 or higher) signs and symptoms or laboratory values. DAIDS Toxicity Grading Table (1992) was used for grading where Grade 1 = transient/mild discomfort, no limitation in activity, no medical intervention; Grade 2 = mild/moderate limitation in activity, some assistance, no/minimal medical intervention; Grade 3 = marked limitation in activity, some assistance, medical intervention required); Grade 4 = extreme limitation in activity, significant medical intervention, assistance, hospitalization.</description>
        <time_frame>Up to 96 Weeks</time_frame>
        <population>All Arm A, B and C participants</population>
        <group_list>
          <group group_id="O1">
            <title>A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).</description>
          </group>
          <group group_id="O3">
            <title>C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)</title>
            <description>At week 12 (end of initial run-in period, Step 1) participants were found to have undetectable HCV RNA (HCV RNA &lt;600 IU/mL) or at least a 2 log10 decrease in HCV RNA from baseline. Participants entered Step 3 and were assigned to continue the run-in treatment (PEG-IFN 180 mcg weekly &amp; RBV1-1.2 g/day based on weight) for a total of 72 weeks. At week 36, participants who had detectable HCV RNA (HCV RNA &gt;=60 IU/mL using a qualitative assay) could enter Step 2 and be randomized to OL PEG-IFN or Observation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With High-grade Signs and Symptoms or Laboratory Values</title>
          <description>Number of participants with high-grade (Grade 3 or higher) signs and symptoms or laboratory values. DAIDS Toxicity Grading Table (1992) was used for grading where Grade 1 = transient/mild discomfort, no limitation in activity, no medical intervention; Grade 2 = mild/moderate limitation in activity, some assistance, no/minimal medical intervention; Grade 3 = marked limitation in activity, some assistance, medical intervention required); Grade 4 = extreme limitation in activity, significant medical intervention, assistance, hospitalization.</description>
          <population>All Arm A, B and C participants</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Grade 3 or higher</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Dose Modifications, Temporary Stops, and Premature Treatment Discontinuations</title>
        <description>3-level categorical of the worst of 1) premature treatment discontinuation, 2) temporary stop or 3) dose reduction. For Arm C, the worst for either PEG-IFN or RBV is summarized.</description>
        <time_frame>Up to 96 Weeks</time_frame>
        <population>All Arm A and C participants. Arm B participants did not receive treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).</description>
          </group>
          <group group_id="O3">
            <title>C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)</title>
            <description>At week 12 (end of initial run-in period, Step 1) participants were found to have undetectable HCV RNA (HCV RNA &lt;600 IU/mL) or at least a 2 log10 decrease in HCV RNA from baseline. Participants entered Step 3 and were assigned to continue the run-in treatment (PEG-IFN 180 mcg weekly &amp; RBV1-1.2 g/day based on weight) for a total of 72 weeks. At week 36, participants who had detectable HCV RNA (HCV RNA &gt;=60 IU/mL using a qualitative assay) could enter Step 2 and be randomized to OL PEG-IFN or Observation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dose Modifications, Temporary Stops, and Premature Treatment Discontinuations</title>
          <description>3-level categorical of the worst of 1) premature treatment discontinuation, 2) temporary stop or 3) dose reduction. For Arm C, the worst for either PEG-IFN or RBV is summarized.</description>
          <population>All Arm A and C participants. Arm B participants did not receive treatment.</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Premature treatment discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temporarily off treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reduced dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Adherent to Study Medications</title>
        <description>A categorical variable with levels adherent and non-adherent based on participants' self report. For Arm A, adherence was defined as not missing PEG within 2 weeks of visit. For Arm C, adherence was defined as not missing any PEG within 2 weeks of visit and not missing RBV within 4 days of visit.</description>
        <time_frame>Arm A: at weeks 12, 24, 48 and 72. Arm C: at entry and weeks 12, 24, 48, 60.</time_frame>
        <population>All Arm A and Arm C participants. Arm B participants did not receive treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).</description>
          </group>
          <group group_id="O3">
            <title>C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)</title>
            <description>At week 12 (end of initial run-in period, Step 1) participants were found to have undetectable HCV RNA (HCV RNA &lt;600 IU/mL) or at least a 2 log10 decrease in HCV RNA from baseline. Participants entered Step 3 and were assigned to continue the run-in treatment (PEG-IFN 180 mcg weekly &amp; RBV1-1.2 g/day based on weight) for a total of 72 weeks. At week 36, participants who had detectable HCV RNA (HCV RNA &gt;=60 IU/mL using a qualitative assay) could enter Step 2 and be randomized to OL PEG-IFN or Observation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Adherent to Study Medications</title>
          <description>A categorical variable with levels adherent and non-adherent based on participants' self report. For Arm A, adherence was defined as not missing PEG within 2 weeks of visit. For Arm C, adherence was defined as not missing any PEG within 2 weeks of visit and not missing RBV within 4 days of visit.</description>
          <population>All Arm A and Arm C participants. Arm B participants did not receive treatment.</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0: Number of participants with adherence data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0: Number of participants adherent to meds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Evaluation not specified in protocol at this timepoint.</measurement>
                    <measurement group_id="O3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12:Number of participants with adherence data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O3" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12:Number of participants adherent to meds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O3" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24:Number of participants with adherence data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24:Number of participants adherent to meds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48:Number of participants with adherence data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48:Number of participants adherent to meds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60:Number of participants with adherence data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60:Number of participants adherent to meds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Evaluation not specified in protocol at this timepoint.</measurement>
                    <measurement group_id="O3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72:Number of participants with adherence data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72:Number of participants adherent to meds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O3" value="NA">Evaluation not specified in protocol at this timepoint.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HCV Polymorphisms</title>
        <description>Due to premature closure of Arms A and B with insufficient number of participants for analysis, this outcome measure was not pursued.</description>
        <time_frame>Entry and week 72 (Arms A and B only).</time_frame>
        <population>Due to premature closure of Arms A and B with insufficient number of participants for analysis, this outcome measure was not pursued. No participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>HCV Polymorphisms</title>
          <description>Due to premature closure of Arms A and B with insufficient number of participants for analysis, this outcome measure was not pursued.</description>
          <population>Due to premature closure of Arms A and B with insufficient number of participants for analysis, this outcome measure was not pursued. No participants were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HCV-specific Immune Response in Intrahepatic Lymphocytes</title>
        <description>Due to premature closure of Arms A and B with insufficient number of participants for analysis, this outcome measure was not pursued.</description>
        <time_frame>Entry and week 72 (Arms A and B only).</time_frame>
        <population>Due to premature closure of Arms A and B with insufficient number of participants for analysis, this outcome measure was not pursued. No participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>HCV-specific Immune Response in Intrahepatic Lymphocytes</title>
          <description>Due to premature closure of Arms A and B with insufficient number of participants for analysis, this outcome measure was not pursued.</description>
          <population>Due to premature closure of Arms A and B with insufficient number of participants for analysis, this outcome measure was not pursued. No participants were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Undetectable HIV Viral Load (&lt;50 Copies/mL)</title>
        <description>A blood sample was drawn to determine the HIV-1 viral load. HIV-1 viral load was categorized as &lt;50 copies/mL (undetectable) or &gt;=50 copies/mL (detectable). 50 is the lower limit of detection of the assay.</description>
        <time_frame>Arms A and B: Weeks 0, 24, 48 and 72; Arm C: Weeks 0, 12, 24, 36, 48, 60, 72, 84</time_frame>
        <population>All Arm A, B, and C participants</population>
        <group_list>
          <group group_id="O1">
            <title>A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).</description>
          </group>
          <group group_id="O3">
            <title>C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)</title>
            <description>At week 12 (end of initial run-in period, Step 1) participants were found to have undetectable HCV RNA (HCV RNA &lt;600 IU/mL) or at least a 2 log10 decrease in HCV RNA from baseline. Participants entered Step 3 and were assigned to continue the run-in treatment (PEG-IFN 180 mcg weekly &amp; RBV1-1.2 g/day based on weight) for a total of 72 weeks. At week 36, participants who had detectable HCV RNA (HCV RNA &gt;=60 IU/mL using a qualitative assay) could enter Step 2 and be randomized to OL PEG-IFN or Observation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Undetectable HIV Viral Load (&lt;50 Copies/mL)</title>
          <description>A blood sample was drawn to determine the HIV-1 viral load. HIV-1 viral load was categorized as &lt;50 copies/mL (undetectable) or &gt;=50 copies/mL (detectable). 50 is the lower limit of detection of the assay.</description>
          <population>All Arm A, B, and C participants</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0: Number of participants with HIV RNA data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0: No. of participants with undetectable VL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Number of participants with HIV RNA data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: No. of participants with undetectable VL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Test not specified in protocol at this timepoint.</measurement>
                    <measurement group_id="O2" value="NA">Test not specified in protocol at this timepoint.</measurement>
                    <measurement group_id="O3" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Number of participants with HIV RNA data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: No. of participants with undetectable VL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36: Number of participants with HIV RNA data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36: No. of participants with undetectable VL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Test not specified in protocol at this timepoint.</measurement>
                    <measurement group_id="O2" value="NA">Test not specified in protocol at this timepoint.</measurement>
                    <measurement group_id="O3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48: Number of participants with HIV RNA data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48: No. of participants with undetectable VL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60: Number of participants with HIV RNA data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60: No. of participants with undetectable VL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Test not specified in protocol at this timepoint.</measurement>
                    <measurement group_id="O2" value="NA">Test not specified in protocol at this timepoint.</measurement>
                    <measurement group_id="O3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72: Number of participants with HIV RNA data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72: No. of participants with undetectable VL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84: Number of participants with HIV RNA data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84: No. of participants with undetectable VL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Test not specified in protocol at this timepoint.</measurement>
                    <measurement group_id="O2" value="NA">Test not specified in protocol at this timepoint.</measurement>
                    <measurement group_id="O3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)</title>
        <description>Insulin resistance was evaluated by HOMA-IR, calculated as [fasting glucose (mg/dL) x fasting insulin (uIU/mL)]/405. Study protocol required fasting for at least 8 hours (nothing by mouth except medications and water) prior to specimen collection for fasting insulin and fasting glucose testing.</description>
        <time_frame>Arms A and B: at entry and weeks 24, 48 and 72; Arm C: at entry and at weeks 12, 24, 36, 48, 72, 84 and 96.</time_frame>
        <population>All Arm A, B and C participants who had HOMA-IR result available. In Arm C, metabolic testing was only performed on participants who enrolled under protocol version 1.0. The number of participants with results available at time points listed in the Time Frame are shown in the Data Table Row Titles below.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).</description>
          </group>
          <group group_id="O3">
            <title>C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)</title>
            <description>At week 12 (end of initial run-in period, Step 1) participants were found to have undetectable HCV RNA (HCV RNA &lt;600 IU/mL) or at least a 2 log10 decrease in HCV RNA from baseline. Participants entered Step 3 and were assigned to continue the run-in treatment (PEG-IFN 180 mcg weekly &amp; RBV1-1.2 g/day based on weight) for a total of 72 weeks. At week 36, participants who had detectable HCV RNA (HCV RNA &gt;=60 IU/mL using a qualitative assay) could enter Step 2 and be randomized to OL PEG-IFN or Observation.</description>
          </group>
        </group_list>
        <measure>
          <title>Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)</title>
          <description>Insulin resistance was evaluated by HOMA-IR, calculated as [fasting glucose (mg/dL) x fasting insulin (uIU/mL)]/405. Study protocol required fasting for at least 8 hours (nothing by mouth except medications and water) prior to specimen collection for fasting insulin and fasting glucose testing.</description>
          <population>All Arm A, B and C participants who had HOMA-IR result available. In Arm C, metabolic testing was only performed on participants who enrolled under protocol version 1.0. The number of participants with results available at time points listed in the Time Frame are shown in the Data Table Row Titles below.</population>
          <units>mg/dL x uIU/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0: HOMA-IR (N=32 in A, 32 in B, 72 in C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.84" lower_limit="2.77" upper_limit="9.03"/>
                    <measurement group_id="O2" value="2.49" lower_limit="1.83" upper_limit="4.48"/>
                    <measurement group_id="O3" value="2.37" lower_limit="1.50" upper_limit="5.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: HOMA-IR (N=72 in C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">HOMA-IR was not collected at Week 12 in Arms A and B.</measurement>
                    <measurement group_id="O2" value="NA">HOMA-IR was not collected at Week 12 in Arms A and B.</measurement>
                    <measurement group_id="O3" value="2.47" lower_limit="1.63" upper_limit="4.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: HOMA-IR (N=34 in A, 30 in B, 73 in C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.08" lower_limit="1.68" upper_limit="5.59"/>
                    <measurement group_id="O2" value="4.78" lower_limit="1.78" upper_limit="6.13"/>
                    <measurement group_id="O3" value="2.58" lower_limit="1.35" upper_limit="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36: HOMA-IR (N=66 in C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">HOMA-IR was not collected at Week 36 in Arms A and B.</measurement>
                    <measurement group_id="O2" value="NA">HOMA-IR was not collected at Week 36 in Arms A and B.</measurement>
                    <measurement group_id="O3" value="2.41" lower_limit="1.44" upper_limit="4.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48: HOMA-IR (N=30 in A, 24 in B, 74 in C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.53" lower_limit="1.72" upper_limit="6.65"/>
                    <measurement group_id="O2" value="2.84" lower_limit="1.78" upper_limit="6.38"/>
                    <measurement group_id="O3" value="3.25" lower_limit="1.73" upper_limit="5.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72: HOMA-IR (N=67 in C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.79" lower_limit="3.41" upper_limit="7.83"/>
                    <measurement group_id="O2" value="4.82" lower_limit="2.46" upper_limit="9.12"/>
                    <measurement group_id="O3" value="2.69" lower_limit="1.66" upper_limit="5.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84: HOMA-IR (N=63 in C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">HOMA-IR was not collected at Week 84 in Arms A and B.</measurement>
                    <measurement group_id="O2" value="NA">HOMA-IR was not collected at Week 84 in Arms A and B.</measurement>
                    <measurement group_id="O3" value="2.99" lower_limit="1.66" upper_limit="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96: HOMA-IR (N=65 in C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">HOMA-IR was not collected at Week 96 in Arms A and B.</measurement>
                    <measurement group_id="O2" value="NA">HOMA-IR was not collected at Week 96 in Arms A and B.</measurement>
                    <measurement group_id="O3" value="2.30" lower_limit="1.63" upper_limit="4.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Virologic Response</title>
        <description>Sustained Virologic Response (SVR) was defined as undetectable HCV viral load (&lt;60 IU/ml) 24 weeks after treatment discontinuation.</description>
        <time_frame>24 weeks after end of treatment</time_frame>
        <population>All Arm A, B and C participants</population>
        <group_list>
          <group group_id="O1">
            <title>A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).</description>
          </group>
          <group group_id="O3">
            <title>C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)</title>
            <description>At week 12 (end of initial run-in period, Step 1) participants were found to have undetectable HCV RNA (HCV RNA &lt;600 IU/mL) or at least a 2 log10 decrease in HCV RNA from baseline. Participants entered Step 3 and were assigned to continue the run-in treatment (PEG-IFN 180 mcg weekly &amp; RBV1-1.2 g/day based on weight) for a total of 72 weeks. At week 36, participants who had detectable HCV RNA (HCV RNA &gt;=60 IU/mL using a qualitative assay) could enter Step 2 and be randomized to OL PEG-IFN or Observation.</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Virologic Response</title>
          <description>Sustained Virologic Response (SVR) was defined as undetectable HCV viral load (&lt;60 IU/ml) 24 weeks after treatment discontinuation.</description>
          <population>All Arm A, B and C participants</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Used Antianorexia Agents, Such as Megestrol and Dronabinol</title>
        <description>Use of antianorexia agents, such as megestrol and dronabinol at any time after pre-assignment.</description>
        <time_frame>Up to 96 weeks</time_frame>
        <population>All Arm A, B and C participants</population>
        <group_list>
          <group group_id="O1">
            <title>A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).</description>
          </group>
          <group group_id="O3">
            <title>C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)</title>
            <description>At week 12 (end of initial run-in period, Step 1) participants were found to have undetectable HCV RNA (HCV RNA &lt;600 IU/mL) or at least a 2 log10 decrease in HCV RNA from baseline. Participants entered Step 3 and were assigned to continue the run-in treatment (PEG-IFN 180 mcg weekly &amp; RBV1-1.2 g/day based on weight) for a total of 72 weeks. At week 36, participants who had detectable HCV RNA (HCV RNA &gt;=60 IU/mL using a qualitative assay) could enter Step 2 and be randomized to OL PEG-IFN or Observation..</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Used Antianorexia Agents, Such as Megestrol and Dronabinol</title>
          <description>Use of antianorexia agents, such as megestrol and dronabinol at any time after pre-assignment.</description>
          <population>All Arm A, B and C participants</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants who used megestrol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants who used dronabinol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Prescription as Needed of Erythropoietin (EPO), Granulocyte Colony-stimulating Factor (GCSF), and Granulocyte-monocyte Colony-stimulating Factor (GM-CSF)</title>
        <description>Prescription as needed of hematologic adjuvant therapies: erythropoietin (EPO), granulocyte colony-stimulating factor (GCSF), and granulocyte-monocyte colony-stimulating factor (GM-CSF) any time after pre-assignment</description>
        <time_frame>At any time after pre-assignment</time_frame>
        <population>All Arm A, B and C participants</population>
        <group_list>
          <group group_id="O1">
            <title>A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).</description>
          </group>
          <group group_id="O3">
            <title>C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)</title>
            <description>At week 12 (end of initial run-in period, Step 1) participants were found to have undetectable HCV RNA (HCV RNA &lt;600 IU/mL) or at least a 2 log10 decrease in HCV RNA from baseline. Participants entered Step 3 and were assigned to continue the run-in treatment (PEG-IFN 180 mcg weekly &amp; RBV1-1.2 g/day based on weight) for a total of 72 weeks. At week 36, participants who had detectable HCV RNA (HCV RNA &gt;=60 IU/mL using a qualitative assay) could enter Step 2 and be randomized to OL PEG-IFN or Observation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Prescription as Needed of Erythropoietin (EPO), Granulocyte Colony-stimulating Factor (GCSF), and Granulocyte-monocyte Colony-stimulating Factor (GM-CSF)</title>
          <description>Prescription as needed of hematologic adjuvant therapies: erythropoietin (EPO), granulocyte colony-stimulating factor (GCSF), and granulocyte-monocyte colony-stimulating factor (GM-CSF) any time after pre-assignment</description>
          <population>All Arm A, B and C participants</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants who used EPO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants who used GCSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants who used GM-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight</title>
        <description>Participant weight in kilograms.</description>
        <time_frame>Arms A and B: at entry and weeks 4, 8, 12, 16, 24, 32, 40, 48, 56, 64 and 72; Arm C: at entry and weeks 4, 8, 12, 16, 24, 36, 48, 72, 84 and 96.</time_frame>
        <population>All Arm A, B and C participants who had weight available. The number of participants with results available at time points listed in the Time Frame are shown in the Data Table Row Titles below.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)</title>
            <description>At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA &gt;=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).</description>
          </group>
          <group group_id="O3">
            <title>C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)</title>
            <description>At week 12 (end of initial run-in period, Step 1) participants were found to have undetectable HCV RNA (HCV RNA &lt;600 IU/mL) or at least a 2 log10 decrease in HCV RNA from baseline. Participants entered Step 3 and were assigned to continue the run-in treatment (PEG-IFN 180 mcg weekly &amp; RBV1-1.2 g/day based on weight) for a total of 72 weeks. At week 36, participants who had detectable HCV RNA (HCV RNA &gt;=60 IU/mL using a qualitative assay) could enter Step 2 and be randomized to OL PEG-IFN or Observation.</description>
          </group>
        </group_list>
        <measure>
          <title>Weight</title>
          <description>Participant weight in kilograms.</description>
          <population>All Arm A, B and C participants who had weight available. The number of participants with results available at time points listed in the Time Frame are shown in the Data Table Row Titles below.</population>
          <units>kilograms</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0: Weight (N=43 in A, 42 in B, 169 in C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.9" lower_limit="67.6" upper_limit="86.8"/>
                    <measurement group_id="O2" value="79.8" lower_limit="69.7" upper_limit="88.3"/>
                    <measurement group_id="O3" value="75.8" lower_limit="68.6" upper_limit="84.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Weight (N=43 in A, 35 in B, 161 in C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.7" lower_limit="68.6" upper_limit="87.4"/>
                    <measurement group_id="O2" value="80.4" lower_limit="70.5" upper_limit="88.5"/>
                    <measurement group_id="O3" value="75.8" lower_limit="68.3" upper_limit="83.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Weight (N=39 in A, 34 in B, 162 in C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.9" lower_limit="66.7" upper_limit="87.3"/>
                    <measurement group_id="O2" value="80.8" lower_limit="71.8" upper_limit="90.9"/>
                    <measurement group_id="O3" value="75.8" lower_limit="67.6" upper_limit="84.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Weight (N=42 in A, 30 in B, 157 in C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.3" lower_limit="67.2" upper_limit="87.9"/>
                    <measurement group_id="O2" value="81.1" lower_limit="69.9" upper_limit="89.9"/>
                    <measurement group_id="O3" value="76.3" lower_limit="67.4" upper_limit="83.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Weight (N=39 in A, 35 in B, 164 in C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.4" lower_limit="67.9" upper_limit="89.5"/>
                    <measurement group_id="O2" value="79.9" lower_limit="70.0" upper_limit="90.4"/>
                    <measurement group_id="O3" value="76.3" lower_limit="66.3" upper_limit="83.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Weight (N=39 in A, 36 in B, 165 in C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5" lower_limit="66.3" upper_limit="89.0"/>
                    <measurement group_id="O2" value="79.4" lower_limit="72.5" upper_limit="91.0"/>
                    <measurement group_id="O3" value="75.8" lower_limit="65.9" upper_limit="82.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Weight (N=37 in A, 35 in B)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5" lower_limit="69.0" upper_limit="88.1"/>
                    <measurement group_id="O2" value="80.4" lower_limit="70.8" upper_limit="87.7"/>
                    <measurement group_id="O3" value="NA">Weight was not collected at Week 32 in Arm C.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36: Weight (N=162 in C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Weight was not collected at Week 36 in Arms A and B.</measurement>
                    <measurement group_id="O2" value="NA">Weight was not collected at Week 36 in Arms A and B.</measurement>
                    <measurement group_id="O3" value="75.0" lower_limit="65.9" upper_limit="84.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Weight (N=32 in A, 29 in B)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.7" lower_limit="67.7" upper_limit="86.4"/>
                    <measurement group_id="O2" value="83.1" lower_limit="70.9" upper_limit="91.0"/>
                    <measurement group_id="O3" value="NA">Weight was not collected at Week 40 in Arm C.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48: Weight (N=33 in A, 31 in B, 153 in C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.2" lower_limit="68.8" upper_limit="88.7"/>
                    <measurement group_id="O2" value="80.4" lower_limit="68.1" upper_limit="93.3"/>
                    <measurement group_id="O3" value="75.1" lower_limit="66.3" upper_limit="84.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56: Weight (N=31 in A, 24 in B)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.7" lower_limit="69.4" upper_limit="92.7"/>
                    <measurement group_id="O2" value="81.6" lower_limit="68.8" upper_limit="90.9"/>
                    <measurement group_id="O3" value="NA">Weight was not collected at Week 56 in Arm C.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64: Weight (N=26 in A, 24 in B)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.5" lower_limit="69.3" upper_limit="87.7"/>
                    <measurement group_id="O2" value="84.0" lower_limit="72.8" upper_limit="91.9"/>
                    <measurement group_id="O3" value="NA">Weight was not collected at Week 64 in Arm C.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72: Weight (N=26 in A, 27 in B, 141 in C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.6" lower_limit="68.6" upper_limit="89.6"/>
                    <measurement group_id="O2" value="85.4" lower_limit="71.7" upper_limit="94.0"/>
                    <measurement group_id="O3" value="75.6" lower_limit="65.5" upper_limit="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84: Weight (N=140 in C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Weight was not collected at Week 84 in Arms A and B.</measurement>
                    <measurement group_id="O2" value="NA">Weight was not collected at Week 84 in Arms A and B.</measurement>
                    <measurement group_id="O3" value="77.0" lower_limit="67.6" upper_limit="87.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96: Weight (N=138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Weight was not collected at Week 96 in Arms A and B.</measurement>
                    <measurement group_id="O2" value="NA">Weight was not collected at Week 96 in Arms A and B.</measurement>
                    <measurement group_id="O3" value="78.4" lower_limit="69.6" upper_limit="88.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From entry (Step 2 for Arms A and B, Step 3 for Arm C) to study completion (at Week 72 for Step 2; at week 78-84 for Step 3, depending on participants' time in Step 1).</time_frame>
      <desc>The protocol required reporting of signs/symptoms and laboratory results &gt;=Grade 3 and events that led to a change in treatment, regardless of grade. Hemoglobin, plateles, ANC, fasting HDL, LDL and total cholesterol, insulin and glucose values were reported regardless of grade. The DAIDS AE Grading Table (1992) and Expedited AE Manual (2004) were used.</desc>
      <group_list>
        <group group_id="E1">
          <title>Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)</title>
          <description>At week 12 (end of the initial run-in period – Step 1) participants were found to be HCV RNA positive (HCV RNA &gt; 60 IU/mL) and had less than a 2 log decrease in HCV RNA from Baseline. For Step 2, participants were assigned to the Randomized Open Label (OL) part of the study to receive the pegylated interferon (PEG-IFN) 180 mcg weekly Arm.</description>
        </group>
        <group group_id="E2">
          <title>OL (PEG-IFN, RBV) Then OL Randomized (Observation)</title>
          <description>At week 12 (end of the initial run-in period – Step 1) participants were found to be HCV RNA positive (HCV RNA &gt; 60 IU/mL) and had less than a 2 log decrease in HCV RNA from Baseline. For Step 2, participants were assigned to the Randomized Open Label (OL) part of the study to be followed on the Observation (no treatment) Arm.</description>
        </group>
        <group group_id="E3">
          <title>OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)</title>
          <description>At week 12 (end of initial run-in period, Step 1) participants were found to be HCV RNA negative (HCV RNA &lt; 60 IU/mL) or had more than a 2 log decrease in HCV RNA from Baseline. Participants were assigned to remain in the Open Label (OL) part of the study continuing the run-in treatment (PEG-IFN 180 mcg weekly &amp; ribavirin [RBV] 1-1.2 g/day based on weight). At the beginning of week 36, participants were retested and, if found to be HCV RNA positive (HCV RNA &gt; 60 IU/mL), participants could be randomized to OL PEG-IFN or Observation.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Neutrophil count</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cerebellar tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="166" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Blood glucose abnormal</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Blood triglycerides abnormal</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="144" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Prothrombin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In accordance with the Clinical Trial Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve US or foreign patent or other intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>ACTG Clinicaltrials.gov Coordinator</name_or_title>
      <organization>ACTG Network Coordinating Center, Social and Scientific Systems, Inc.</organization>
      <phone>(301) 628-3313</phone>
      <email>ACTGCT.Gov@s-3.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

